Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2007) 14 P192

ECE2007 Poster Presentations (1) (659 abstracts)

Pioglitazone modifies the effects of growth hormone on lipolysis and insulin sensitivity

Morten B Krag 1 , Søren Nielsen 1 , ZengKui Guo 2 , Steen B Pedersen 3 , Ole Schmitz 1 , Jens S Christiansen 1 & Jens OL Jørgensen 1

1Medical Department M, Aarhus University Hospital, DK-8000 Aarhus C, Denmark; 2Endocrine Research Unit, Mayo Clinic, Rochester, MN 55905, United States; 3Medical Department C, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.

Context: Thiazolidiones (TZD) improves insulin sensitivity in type 2 diabetes via effects on fat metabolism, whereas growth hormone (GH) stimulates lipolysis and induces insulin resistance.

Objective: To evaluate the effects of TZD on fat metabolism and insulin sensitivity in GH-treated GH deficient (GHD) patients.

Design: Randomized, placebo-controlled, double-blind parallel-group study including 20 GHD patients on continued GH replacement therapy. The patients were studied before and after 12 weeks.

Intervention: Patients received either tablet pioglitazone 30 mg (N=10) or placebo (N=10) once daily for 12 weeks.

Results: 12 weeks of pioglitazone treatment in GH-replaced GHD patients was associated with improved insulin sensitivity (P=0.03) and increased basal glucose oxidation (P=0.004). Change in insulin-stimulated adiponectin level after pioglitazone treatment was positive correlated to the change in insulin-stimulated total glucose disposal (R=0.69, P=0.04). Pioglitazone significantly decreased basal free fatty acid levels (P=0.02) and lipid oxidation (P=0.02). Adiponectin levels almost doubled during pioglitazone treatment (P=0.0001).

Conclusion: The impact of GH on lipolysis and insulin sensitivity is modified by administration of PPARγ agonists.

Article tools

My recent searches

No recent searches.